Record Fine For Pfizer Throws Spotlight On UK Generic Pricing
Executive Summary
Following the decision by the UK competition authority to fine Pfizer and Flynn Pharma for “unfair and excessive” pricing, generic prices are to be brought under tighter government control. But it remains to be seen how these controls will be applied in practice where companies are suspected of excessive pricing, and exactly what might constitute an “unreasonable price,” say Gustaf Duhs and Astrid Arnold.